These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32308099)

  • 1. Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States.
    Bungey G; Chang-Douglass S; Hsu MA; Cappelleri JC; Young P; Woolcott J
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1027-1038. PubMed ID: 32308099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.
    Claxton L; Taylor M; Gerber RA; Gruben D; Moynagh D; Singh A; Wallenstein GV
    Curr Med Res Opin; 2018 Nov; 34(11):1991-2000. PubMed ID: 29976110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
    Wehler E; Boytsov N; Nicolay C; Herrera-Restrepo O; Kowal S
    Pharmacoeconomics; 2020 Jan; 38(1):39-56. PubMed ID: 31452079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of introducing tofacitinib to the public hospital formulary in Hong Kong, 2017-2021.
    Li X; Pathadka S; Man KK; Wong ICK; Chan EWY
    Hong Kong Med J; 2019 Jun; 25(3):201-208. PubMed ID: 31178440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims Databases.
    Mease PJ; Papademetriou E; Potluri R; Agarwal E; Cappelleri JC; Ling YL
    Adv Ther; 2024 Oct; 41(10):3850-3867. PubMed ID: 39143312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
    Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
    Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Dai Q; Zhang Y; Liu Q; Zhang C
    Clin Rheumatol; 2024 May; 43(5):1605-1613. PubMed ID: 38517652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
    Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain.
    Navarro F; Martinez-Sesmero JM; Balsa A; Peral C; Montoro M; Valderrama M; Gómez S; de Andrés-Nogales F; Casado MA; Oyagüez I
    Clin Rheumatol; 2020 Oct; 39(10):2919-2930. PubMed ID: 32303858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
    Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
    Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.